ClinicalTrials.gg
Not yet recruitingNCT07949656Updated Nov 19, 2026

Anisodine Hydrobromide for Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib Dose-Escalation Study

A Phase 1 interventional study of Anisodine Hydrobromide in Acute Ischemic Stroke and Vertebrobasilar Artery Occlusion, sponsored by The Affiliated Hospital of Xuzhou Medical University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Affiliated Hospital of Xuzhou Medical University · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is an investigator-initiated Phase Ib clinical trial employing a prospective, single-center, open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of anisodine hydrobromide in patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment and to determine the recommended dose for subsequent clinical studies.

Read the detailed description

This study is an investigator-initiated, prospective, single-center Phase Ib clinical trial designed to evaluate the safety and tolerability of anisodine hydrobromide administered to patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment. The trial adopts an open-label, non-randomized, 3+3 dose-escalation design to identify the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D).

02

Conditions studied

  • Acute Ischemic Stroke
  • Vertebrobasilar Artery Occlusion

Browse trials for

Keywords

  • Acute vertebrobasilar artery occlusion
  • Basilar artery occlusion
  • Posterior circulation stroke
  • Endovascular thrombectomy
  • Anisodine hydrobromide
  • Acute ischemic stroke
  • Dose escalation
03

In context

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

This study's planned enrollment of 24 is below the median of 120 across 1,785 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

The Affiliated Hospital of Xuzhou Medical University is the lead sponsor of 71 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Time from stroke onset to first dose of study medication ≤24 hours.
  4. Imaging-confirmed acute vertebrobasilar artery occlusion (VBAO), including basilar artery occlusion, bilateral intracranial vertebral artery occlusion, or vertebrobasilar tandem occlusion.
  5. Eligible for and planned to undergo emergency endovascular treatment.
  6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6.
  7. Posterior circulation Alberta Stroke Program Early CT Score (pcASPECTS) ≥6.
  8. No definite extensive irreversible infarction on posterior circulation imaging assessment.
  9. Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  10. Written obtained from the participant or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.
  2. History of congenital or acquired bleeding disorders, coagulation factor deficiencies, or thrombocytopenic disorders.
  3. Vascular anatomical conditions expected to prevent successful completion of endovascular treatment.
  4. Known severe allergy to iodinated contrast media.
  5. Pregnancy or breastfeeding, or planning to become pregnant during the study period or within 90 days after enrollment.
  6. Known allergy to anisodine hydrobromide or a history of severe intolerance following previous administration.
  7. Concomitant clinical conditions that may be exacerbated by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention, prostatic hypertrophy with difficulty urinating, or paralytic ileus.
  8. Severe cardiac arrhythmias (e.g., tachyarrhythmias requiring electrical cardioversion or recurrent syncope) or hemodynamic instability (e.g., requiring vasopressors or persistent hypotension).
  9. Severe psychiatric disorders, dementia, or impaired consciousness that would prevent the participant from providing or completing follow-up.
  10. or other severe systemic diseases with an expected survival of less than 90 days.
  11. Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.
  12. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Anisodine Hydrobromide 1.0 mg

    Participants receive anisodine hydrobromide 1.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

    Drug: Anisodine Hydrobromide

  • Experimental
    Anisodine Hydrobromide 1.5 mg

    Participants receive anisodine hydrobromide 1.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

    Drug: Anisodine Hydrobromide

  • Experimental
    Anisodine Hydrobromide 2.0 mg

    Participants receive anisodine hydrobromide 2.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

    Drug: Anisodine Hydrobromide

  • Experimental
    Anisodine Hydrobromide 2.5 mg

    Participants receive anisodine hydrobromide 2.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

    Drug: Anisodine Hydrobromide

Interventions

  • DrugAnisodine Hydrobromide

    Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization. In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Occurrence of Predefined Safety Events Within 8 Days

    The primary safety outcome is the occurrence of predefined safety events within 8 consecutive days after the first administration of the study drug. Predefined safety events include: (1) symptomatic intracranial hemorrhage (sICH), defined as intracranial hemorrhage confirmed by neuroimaging in conjunction with neurological deterioration, operationalized as an increase of at least 4 points in the NIHSS score; (2) death from any cause; and (3) any other serious adverse event (SAE), excluding the foregoing events, that is adjudicated by the Data Monitoring Committee (DMC) to be definitely, probably, or possibly related to the study drug.

    Time frame: Within 8 days after the first administration

Secondary outcomes

  1. Early Neurological Deterioration

    Early neurological deterioration is defined as worsening in neurological status within 24 hours after treatment initiation. Neurological status is assessed using the National Institutes of Health Stroke Scale (NIHSS), a validated clinical instrument for assessing stroke severity. The NIHSS total score ranges from 0 to 42, with higher scores indicating greater neurological impairment.

    Time frame: Within 24 hours after treatment initiation

  2. Infarct Volume

    Infarct volume measured on non-contrast cranial computed tomography (CT) at Day 8, expressed in milliliters (mL).

    Time frame: Day 8

  3. Functional Outcome (Modified Rankin Scale)

    Functional outcome assessed using the modified Rankin Scale (mRS) at Day 90. The mRS score ranges from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. The distribution of mRS scores will be reported.

    Time frame: Day 90

  4. Incidence of Symptomatic Intracranial Hemorrhage

    Incidence of symptomatic intracranial hemorrhage (sICH) confirmed by neuroimaging and accompanied by neurological deterioration, defined as an increase of at least 4 points in the NIHSS score, within 8 days after the first administration of the study drug.

    Time frame: Within 8 days after the first administration

  5. Incidence of Any Intracranial Hemorrhage

    Incidence of any intracranial hemorrhage detected by neuroimaging within 8 days after the first administration of the study drug, regardless of whether neurological deterioration is present.

    Time frame: Within 8 days after the first administration

  6. Incidence of Study Drug-Related Adverse Events

    Incidence of adverse events (AEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

    Time frame: Within 90 days after the first administration

  7. Incidence of Study Drug-Related Serious Adverse Events

    Incidence of serious adverse events (SAEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

    Time frame: Within 90 days after the first administration

  8. All-Cause Mortality

    All-cause mortality occurring within 90 days after the first administration of the study drug.

    Time frame: Within 90 days after the first administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Jan 20, 2027
CompletionEst.
Jan 20, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949656
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Jan 20, 2027 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Yu Feng, MD, PhD
Contact
xyfysjnkfy@126.com
+86-15252148124
Zihao Jiao
Contact
medicinejzh@126.com
+86-17596062986
Yu Feng, MD, PhD
principal investigator · The Affiliated Hospital of Xuzhou Medical University
Yanbo Cheng, MD, PhD
study director · The Affiliated Hospital of Xuzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion